Humanigen, Inc.

Humanigen has discovered, developed, and plans to commercialize LENZ® (lenzilumab), a variant-agnostic immunomodulatory antibody, which addresses a significant unmet need in COVID-19.

LENZ® represents a near-term opportunity in COVID-19 with a defined regulatory pathway, a first-line positioning patient segment not addressed by current therapies, and potential for multi-billion dollar annual recurring revenues.

Nasdaq: HGEN
IR Website:
Headquarters: Short Hills, NJ

Content provided by Humanigen on 2-22-22.


The Humanigen management team is always available to talk to current and potential investors. They're happy to answer any questions you may have and tell you what makes their story unique. Please fill out this form, and we will connect you shortly.


Business Development Fact Sheet

Management Overview

Risks & Disclosures